Please login to the form below

Not currently logged in
Email:
Password:

Fat-derived stem cells may treat MS

A preliminary study of the use of fat stem cells to treat three MS patients has resulted in a dramatic improvement in the condition of all three patients and could pave the way for further clinical trials

A preliminary study of the use of fat stem cells (taken from the patient's abdominal fat tissue) to treat three MS patients has resulted in a dramatic improvement in the condition of all three patients and could pave the way for further clinical trials. The results suggest that the use of stromal vascular fraction (SVF) might be beneficial for those with other autoimmune diseases too.  

Dr Boris Minev, at the division of neurosurgery, University of California said: "While obviously no conclusions in terms of therapeutic efficacy can be drawn from these reports, this first clinical use of fat stem cells for treatment of MS supports further investigation into this very simple and easily-implementable treatment methodology."

In the UK approximately 85,000 people have MS (the most common disabling neurological condition affecting young adults). The technique involved in SVF is simple and involves fatty tissue being removed from the patient using liposuction. A week later, and after a filtering process, millions of stromal vascular fraction cells are injected into the patient. In animal studies, it has been found that these cells make their way to damaged areas of the brain and nervous system, and also lungs and liver. In humans, it is not yet clear how the cells lead to improvements, but it is possible they may help heal the immune system.

The study is published in the Journal of Translational Medicine.

27th April 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
emotive.

emotive. is an award-winning healthcare communications agency working with leading global and EMEA companies in life sciences including medical device...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...

Infographics